Emergent BioSolutions Receives Award to Supply 44.75 Million Doses of BioThrax to U.S. Government over Five Years
Emergent BioSolutions Inc. (NYSE: EBS) today announced that, in response to solicitation RFP-2011-N-13414, it has received an award to supply the U.S. government with 44.75 million doses of...
Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference in London
ROCKVILLE, Md., Sep 14, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Jefferies 2011 Global...
Emergent BioSolutions Co-Hosts Biopreparedness Conference with the French High Committee for Civil Defense
Emergent BioSolutions Inc. (NYSE:EBS) is co-hosting "Anthrax: Threat and Response," a conference organized by the French High Committee for Civil Defense to discuss anthrax preparedness and response....
Results of Emergent BioSolutions Phase 1a Study on Adjuvanted BioThrax Anthrax Vaccine Published in the Journal Vaccine
Emergent BioSolutions Inc. (NYSE:EBS) announced today that results from a Phase 1a clinical trial evaluating an investigational anthrax vaccine, Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant mixed...
Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed – Indolent Lymphoma
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1b/2 study (16011) of TRU-016 in combination with rituximab and bendamustine for patients with relapsed indolent...
New Tuberculosis Vaccine Enters Phase IIb Proof-of-Concept Trial in People Living with HIV in Senegal and South Africa
Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) announce today the start of a Phase IIb proof-of-concept efficacy trial of a new investigational tuberculosis (TB) vaccine that involves...
Emergent BioSolutions to Present at Wedbush 2011 Life Sciences Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Wedbush 2011 Life Sciences Conference in New York on Wednesday, August 17, 2011 at...
Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2011
Emergent BioSolutions Inc. Investor Contact: Robert G. Burrows Vice President, Investor Relations 301-795-1877 BurrowsR@ebsi.com or Media Contact: Tracey Schmitt Vice President, Corporate...
Emergent BioSolutions to Release Second Quarter 2011 Financial Results and Conduct a Conference Call on August 4, 2011
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the second quarter 2011 on Thursday, August 4, 2011, after market...
Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Singapore Health Sciences Authority (HSA) has approved Emergent's product license application for the marketing and sale of BioThrax(R)...
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Appointed to U.S. Chamber of Commerce Board of Directors
Emergent BioSolutions Inc. (NYSE:EBS) announced today that its Chairman and Chief Executive Officer, Fuad El-Hibri, has been appointed to serve on the Board of Directors of the U.S. Chamber of...
Emergent BioSolutions’ Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation
Emergent BioSolutions Inc. (NYSE:EBS) announced today that its investigational anthrax vaccine, NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), has been granted Fast Track Designation by...